Premium
Resveratrol potentially increased the tumoricidal effect of doxorubicin on SKOV3 cancer stem cells in vitro
Author(s) -
Pouyafar Ayda,
Zadi Heydarabad Milad,
Aghdam Sina Bahar,
Khaksar Majid,
Azimi Ako,
Rahbarghazi Reza,
Talebi Mehdi
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.28129
Subject(s) - cancer stem cell , multiple drug resistance , apoptosis , viability assay , doxorubicin , rhodamine 123 , resveratrol , cancer research , population , pharmacology , cancer cell , drug resistance , cancer , ovarian cancer , side population , stem cell , biology , chemistry , chemotherapy , medicine , microbiology and biotechnology , biochemistry , environmental health
Abstract Ovarian cancer is associated with a high percentage of recurrence of tumor and resistance to chemotherapy. Cancer stem cells (CSCs) form a rare population with a significant capacity to begin and expand malignant diseases. Eliminating the drug resistance of CSCs by factors that have fewer side effects to the patient is vital. To investigate the effect of resveratrol (RES) and doxorubicin (DOX) on drug resistance and apoptosis of CSCs; at the first, isolation of CSCs from SKOV3 ovarian carcinoma cells and their dosage adjustment (IC 50 ) with RES and DOX was performed. Then, isolated CSCs were treated with RES and DOX IC 50 of 55 and 250 nM, respectively. Subsequently, their effects on drug resistance and cell death were evaluated using real‐time polymerase chain reaction, rhodamine 123 uptakes. The results of the present study demonstrated that treatment of SKOV3 with 55 μM of RES and 250 nM of DOX simultaneously increased cell viability in CSCs to DOX after 24 and 48 hours by increasing the expression of Bcl‐2‐associated X protein (BAX) and caspase‐3 genes, and decreased the expression and function of multidrug resistance protein 1 (MDR1) and multidrug resistance‐associated protein 1 (MRP1) genes indicated by intracellular the rhodamine 123 content. Treatment of RES could increase the activity of DOX cell viability in CSCs originated from SKOV3 ovarian carcinoma and decrease drug resistance capacity to DOX.